Allogene Therapeutics, Inc. Expense Breakdown
No Expense Breakdown for ALLO on this site yet.
- 2026-06-30: Reportable $51.56M.
- 2025-06-30: Reportable $56.82M.
Source checked: the stored Expense Breakdown page for ALLO.
Expenses by product
Operating expenses: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $51.56M |
| 2025-06-30 | $56.82M |
Research And Development Expense Cema Cel: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $6.95M |
| 2025-06-30 | $6.87M |
Research And Development Expense Other Development Costs: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $2.41M |
| 2025-06-30 | $4.90M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |